HER2

HER2 is named as such due to structural similarities with human epidermal growth factor receptor 1, or HER1. The Neu alias of HER2 derives its name from the parent glioblastoma cell line - a type of neural tumor found in rodents. ErbB-2 was named for its similarity to avian erythroblastosis oncogene B, ErbB; the oncogene later shown to code for epidermal growth factor receptor, EGFR. Molecular cloning of EGFR discovered that HER2, Neu, and ErbB-2 are all encoded by the same orthologs. == Gene ==

ERBB2, a known proto-oncogene, is located at the long arm of human chromosome 17 (17q12). == Function ==

The ErbB family consists of four individual plasma membrane-bound receptor tyrosine kinases. One of these is erbB-2; the other members are erbB-1, erbB-3 (neuregulin-binding; lacks kinase domain), and erbB-4. All four contain an extracellular ligand binding domain, a transmembrane domain, and an intracellular domain that can interact with a multitude of signaling molecules and exhibit both ligand-dependent and ligand-independent activity. Notably, no ligands for HER2 have yet been identified. HER2 can heterodimerise with any of the other three receptors and is considered to be the preferred dimerisation partner of the other ErbB receptors. Dimerisation results in the clustering of receptors within lipid rafts and autophosphorylation of tyrosine residues within the cytoplasmic domain of the receptors to activate a variety of signaling pathways. Signal transduction Signaling pathways activated by HER2 include: • mitogen-activated protein kinase (MAPK) • phosphoinositide 3-kinase (PI3K/Akt) • phospholipase C γ • protein kinase C (PKC) • signal transducer and activator of transcription (STAT) In summary, signaling through the ErbB family of receptors promotes cell proliferation and opposes apoptosis, and therefore must be tightly regulated to prevent uncontrolled cell growth from occurring. == Clinical significance ==

Cancer Amplification, also known as over-expression of the ERBB2 gene, occurs in approximately 10-30% of breast cancers. HER2-positive breast cancers are associated with increased disease recurrence and a poor prognosis compared with other identifiably genetically distinct breast cancers; however, drug agents targeting HER2 have significantly and positively altered the otherwise poor prognosis of HER2-positive breast cancer. Over-expression of HER2 is also known to occur in adenocarcinomas of the lung, ovary, and stomach, and in aggressive forms of uterine cancer, such as uterine serous carcinoma. E.g., HER2 is over-expressed in approximately 7-34% of patients with gastric cancer and in 30% of salivary duct carcinomas. The ERBB2 gene is physically near the gene encoding GRB7 on chromosome 17. GRB7 is a proto-oncogene associated with breast, testicular germ cell, gastric, and esophageal tumours and is frequently co-amplified in cancer cells with HER2 amplification. The high expression of HER2 correlates with better survival in esophageal adenocarcinoma. The high amplification of HER2 copy number positively contributes to the survival time of gastric cardia adenocarcinoma patients. Mutations Furthermore, diverse structural alterations have been identified that cause ligand-independent firing of this receptor, doing so in the absence of receptor over-expression. HER2 is found in a variety of tumours and some of these tumours carry point mutations in the sequence specifying the transmembrane domain of HER2. Substitution of a valine for a glutamic acid or a glutamine in the transmembrane domain can result in the constitutive dimerisation of this protein in the absence of a ligand. HER2 mutations have been found in non-small-cell lung cancers (NSCLC) and can direct treatment. == As a drug target ==

HER2 is the target of the monoclonal antibody trastuzumab (marketed as Herceptin). Trastuzumab is effective only in cancers where HER2 is over-expressed. One year of trastuzumab therapy is recommended for all patients with HER2-positive breast cancer who are also receiving chemotherapy. Randomized trials have demonstrated no additional benefit beyond 12 months, whereas 6 months has been shown to be inferior to 12. Trastuzumab is administered intravenously weekly or every 3 weeks. An important downstream effect of trastuzumab binding to HER2 is an increase in p27, a protein that halts cell proliferation. Another monoclonal antibody, Pertuzumab, which inhibits dimerisation of HER2 and HER3 receptors, was approved by the FDA for use in combination with trastuzumab in June 2012. As of November 2015, there are a number of ongoing and recently completed clinical trials of novel targeted agents for HER2+ metastatic breast cancer, e.g. margetuximab. Additionally, NeuVax (Galena Biopharma) is a peptide-based immunotherapy that directs "killer" T cells to target and destroy cancer cells that express HER2. It has entered phase 3 clinical trials. It has been found that patients with ER+ (estrogen receptor positive)/HER2+ compared with ER-/HER2+ breast cancers may actually benefit more from drugs that inhibit the PI3K/AKT molecular pathway. Over-expression of HER2 can also be suppressed by the amplification of other genes. Research is currently being conducted to discover which genes may have this desired effect. The expression of HER2 is regulated by signaling through estrogen receptors. Normally, estradiol and tamoxifen acting through the estrogen receptor down-regulate the expression of HER2. However, when the ratio of the coactivator AIB-3 exceeds that of the corepressor PAX2, the expression of HER2 is upregulated in the presence of tamoxifen, leading to tamoxifen-resistant breast cancer. Among approved anti-HER2 therapeutics are also tyrosine kinase inhibitors (such as lapatinib, neratinib, and tucatinib) and antibody-drug conjugates (ado-trastuzumab emtansine and trastuzumab deruxtecan). == Diagnostics ==

HER2 testing is performed on breast biopsy of breast cancer patients to assess prognosis and to determine suitability for trastuzumab therapy. It is important that trastuzumab is restricted to HER2-positive individuals as it is expensive and has been associated with cardiac toxicity. For HER2-positive tumors, the benefits of trastuzumab clearly outweigh the risks. Tests are usually performed on breast biopsy samples obtained by either fine-needle aspiration, core needle biopsy, vacuum-assisted breast biopsy, or surgical excision. Immunohistochemistry (IHC) is generally used to measure the amount of HER2 protein present in the sample, with fluorescence in situ hybridisation (FISH) being used on samples that are equivocal in IHC. However, in several locations, FISH is used initially, followed by IHC in equivocal cases. Immunohistochemistry By immunohistochemistry, the sample is given a score based on the cell membrane staining pattern. Micrographs showing each score: File:HER2 immunohistochemistry with 0 pattern.png|0 File:HER2 immunohistochemistry with 1 plus pattern.png|1+ File:HER2 immunohistochemistry with 2 plus pattern.png|2+ File:HER2 immunohistochemistry with 3 plus pattern.png|3+ Fluorescence in situ hybridisation FISH can be used to measure the number of copies of the gene which are present and is thought to be more reliable than immunohistochemistry. It usually uses chromosome enumeration probe 17 (CEP17) to count the amount of chromosomes. Hence, the HER2/CEP17 ratio reflects any amplification of HER2 as compared to the number of chromosomes. The signals of 20 cells are usually counted. File:HER2 FISH with 2 HER2 signals and 3 CEP17 signals.png|This cell displays 2 signals of HER2 (red) and 3 signals of CEP17 (green) File:Counting one or two signals on HER2 FISH.png|Two signals that are closer to each other than the signal diameter count as one. File:HER2 FISH with debris.png|One of these signals is too faint, and is presumably debris. File:HER2 FISH with only one signal type.jpg|Cells with only one type of signal are excluded from the count. File:HER2 FISH with overlapping cells.png|Overlapping cells are also excluded from the count. File:HER2 FISH with a yellow signal.png|A yellow signal counts as one red and one green (which are overlapping) File:Counting HER2 versus CEP17 probes in FISH of HER2 amplified cell.png File:HER2 FISH algorithm.svg|Algorithm for the evaluation of HER2 on fluorescence in situ hybridization (FISH). If the initial HER2 result is negative for a needle biopsy of a primary breast cancer, a new HER2 test may be performed on the subsequent breast excision. However, its ability to determine eligibility for trastuzumab therapy is less clear. == Interactions ==

HER2/neu has been shown to interact with: • CTNNB1 • DLG4 • Erbin • GRB2 • HSP90AA1 • IL6ST • MUC1 • PICK1 • PLCG1 and • SHC1 == See also ==